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Two Cases of Transfusion-related Acute Lung Injury Triggered  
by HLA and Anti-HLA Antibody Reaction
Transfusion-related acute lung injury (TRALI) is a serious adverse transfusion reaction that is 
presented as acute hypoxemia and non-cardiogenic pulmonary edema, which develops 
during or within 6 hr of transfusion. Major pathogenesis of TRALI is known to be related 
with anti-HLA class I, anti-HLA class II, or anti-HNA in donor’s plasma. However, anti-HLA 
or anti-HNA in recipient against transfused donor’s leukocyte antigens also cause TRALI in 
minor pathogenesis and which comprises about 10% of TRALI. Published reports of TRALI 
are relatively rare in Korea. In our cases, both patients presented with dyspnea and 
hypoxemia during transfusion of packed red blood cells and showed findings of bilateral 
pulmonary infiltrations at chest radiography. Findings of patients’ anti-HLA antibodies and 
recipients’ HLA concordance indicate that minor pathogenesis may be not as infrequent as 
we’d expected before. In addition, second case showed that anti-HLA class II antibodies 
could be responsible for immunopathogenic mechanisms, alone.
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Transfusion-related acute lung injury (TRALI) is typically pre-
sented as pulmonary edema with bilateral pulmonary infiltra-
tions on chest radiography and severe dyspnea, tachypnea and 
cyanosis which develops during or within 6 hr of transfusion 
(1). The diagnostic criteria was proposed by TRALI Consensus 
Conference in 2004 (Table 1) (2). Most patients having suspect-
ed TRALI require supplemental oxygen and approximately 70% 
of affected patients require mechanical ventilation. Although 
the estimated incidence of TRALI is 1 in 5,000 and the mortality 
is 6%, the true frequency is not known (1, 3). Suspected cases of 
TRALI may have been misdiagnosed or underestimated until 
now due to the poor awareness or lack of laboratory evidence.
  Many studies revealed that the mechanism of TRALI is trig-
gered by the presence of anti-human leukocyte antigen (anti-
HLA) or anti-human neutrophil antigen (anti-HNA) antibodies 
present in plasma of donor and/or recipient. The identification 
of anti-HLA or anti-HNA antibodies in plasma of donor and/or 
recipient supports the diagnosis of TRALI (2).
  Although there are a few documented reports about TRALI 
in Korea, the identification of immunopathogenic evidence 
was not performed sufficiently (4). Recently, we’ve experienced 
two cases of TRALI triggered by  patients’ anti-HLA antibodies 
which were specific for HLAs of transfused packed red blood 
cells (PRBC). Clinical manifestations as well as the findings of 
donors’ and patients’ HLA and anti-HLA concordance strongly 




A 66-yr-old man having lung cancer with fibrosis was admitted 
through emergency room due to dyspnea on August 25, 2008. 
The initial vital signs were blood pressure 97/56 mmHg, pulse 
rate 77/min, respiratory rate 22/min and body temperature 
37.3°C and laboratory findings were SpO2 80% and 3,960/µL-
10.0 gm/dL-124×10
3/µL for white blood cells (WBC)–hemoglo-
bin (Hb)-platelet, respectively. On the second hospital day, pan-
cytopenia became aggravated (2,810/µL-7.8 gm/dL-72×10
3/µL 
for WBC-Hb-platelet, respectively), so transfusion of 2 units of 
PRBC was planned to correct anemia. He was transfused the 
first unit of PRBC without any adverse transfusion reactions. 
Approximately 5 min after starting transfusion of the second unit 
of PRBC, the patient presented dyspnea, cyanosis and shivering 
with elevation of body temperature (38°C), He developed severe 
respiratory failure (SaO2 <50%, PaCO2 25.7 mmHg, PaO2 25.8 
mmHg, respiratory rate >60/min) and hypotension (systolic 
blood pressure <70 mmHg). Intubation and mechanical venti-
lation were required to maintain adequate oxygenation. The 
chest radiograpy taken after intubation showed interval aggra-Lee JH, et al.  •  Transfusion-related Acute Lung Injury
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vation of bilateral diffuse ground glass opacity of lung paren-
chyma with pleural effusion but with normal cardiothoracic ra-
tio (Fig. 1B). 
  The echocardiogram taken soon after the patient was trans-
ferred to the intensive care unit showed normal LV cavity size 
and moderate LV systolic dysfunction (LV ejection fraction was 
39%) with mild aortic regurgitation. And there was no evidence 
of pulmonary embolism or acute myocardial infarction. The 
patient did not have any clinical signs of transfusion associated-
circulatory overload (TACO) such as jugular venous distension, 
systolic hypertension or gallop. B-type natriuretic peptide (BNP) 
(Triage, Biosite, United Kingdom) level measured an hour after 
the event of respiratory failure was 106 pg/mL which was slightly 
elavated (reference range 5-100 pg/mL). It has been suggested 
that if the level of BNP is higher than 250 pg/mL, it is indicative 
of congestive heart failure, but if less than 150 pg/mL, TRALI is 
more likely (5). Acute hemolytic transfusion reaction also has 
been excluded based on repeated compatible serologic cross-
match result and absence of typical clinical features such as he-
moglobinuria, decreased hemoglobin level or renal failure. One 
month ago, he had been transfused with 2 units of PRBC with-
out any adverse transfusion reactions. Since there were no an-
gioedema, wheezing, strigor or urticaria, the diagnosis of ana-
phylactic transfusion reaction was also excluded.
  Patient’s pre- and post-transfusion blood samples and rem-
nants of 2 units of transfused PRBC were subjected to further 
immunologic studies. HLA typing and tests for panel reactive 
antibody (PRA) were performed by PCR-SSP (Biotest, Germa-
ny) and ELISA (GTI, USA), respectively. Prior to transfusion, the 
patient already had multiple anti-HLA antibodies (Anti-A32, 
Anti-DR8) which were specific for HLA type of PRBC (first PRBC: 
A*32/DR8 and second PRBC: A*33/CREGs). And the % PRAs of 
patient’s serum after transfusion were further increased to 40% 
(Anti-A1, -A25, -A32, -B37, -B45, -B51, -B63) and 37% (Anti-DR8, 
-DR52) of anti-HLA class I and II antibodies, respectively. The 
spectrum of donor specific anti-HLA antibodies became broad-
ened and the titers were elevated (Table 2). 
  The patient was managed under ventilatory support with ino-
tropics. There was no clinical improvement in pulmonary com-
plications and the patient could not wean ventilator support.
Table 1. Diagnostic criteria for TRALI and possible TRALI (TRALI Consensus Conference 
in Toronto, Canada, on April 1 and 2, 2004)
1. TRALI criteria
    a. ALI
          i. Acute onset
         ii. Hypoxemia
                 Research setting: PaO2/FiO2 ≤300, or SpO2 <90% on room air
                 Nonresearch setting: PaO2/FiO2 ≤300, or SpO2 <90% on room air or 
                     other clinical evidence of hypoxemia
        iii. Bilateral infiltrations on chest X-ray
        iV. No evidence of left atrial hypertension (i.e., circulatory overload)
    b. No preexisting ALI before transfusion
    c. During or within 6 hr of transfusion
    d. No temporal relationship to an alternative risk factor for ALI
2. Possible TRALI
    a. ALI
    b. No preexisting ALI before transfusion
    c. During or within 6 hr of transfusion
    d. A clear temporal relationship to an alternative risk factor for ALI
TRALI, transfusion-related ALI; ALI, acute lung injury; PaO2, partial pressure of oxygen 
in arterial blood; FiO2, fraction of inspired oxygen; SpO2, saturation of hemoglobin with 
oxygen as measured by pulse oximetry.
A B
Fig. 1. Chest radiography of the Case 1. (A) 1 day before the transfusion of packed red blood cells (B) shortly after TRALI develops, showing aggravated bilateral lung infiltrations 
with pleural effusion.Lee JH, et al.  •  Transfusion-related Acute Lung Injury
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Case 2
A 62-yr-old woman was hospitalized for palliative treatment of 
rectal cancer with multiple lung metastasis on October 1. 2008. 
She was under anti-hypertensive medications for 10 yr. On the 
9th hospital day, she complained of mild dyspnea and had a ra-
diological finding compatible with mild pulmonary edema (Fig. 
2A). On the 13th hospital day, transfusion of 8 units of platelet 
concentrates (PC) and 2 units of PRBC were planned to correct 
thrombocytopenia and anemia (7,880/µL-8.0 g/dL-9×10
3/µL 
for WBC-Hb-platelet, respectively). She had transfusion histo-
Table 2. Summary of the clinical features and the results of PRA identification and HLA typing in 2 cases of TRALI
Case 1 Case 2
Clinical features of patients  66-yr-old male with lung cancer
About 5 min after starting transfusion of the second unit of PRBC 
Dyspnea, cyanosis and shivering, severe respiratory failure  
(SaO2 <50%)
62-yr-old female with rectal cancer
Results of PRA Identification in patients
Anti-HLA Class I In patient’s serum before the transfusion
    PRA: 10%
    Specificity: Anti-A32
In patient’s serum after the transfusion
    PRA: 40%
    Specificity: Anti-A32, -A1, -A25
                     Anti-B45, -B51, -B37, -B63
After transfusion of approximately 30 mL of the first unit of PRBC 
Aggravated dyspnea, decreased SpO2 (85%)
Patient’s serum after the transfusion
    PRA: negative
Anti-HLA Class II In patient’s serum before the transfusion
    PRA: 10%
    Specificity: Anti-DR8
In patient’s serum after the transfusion
    PRA: 37%
    Specificity: Anti-DR8, -DR52
Patient’s serum after the transfusion
    PRA: 37%
    Specificity: Anti-DR4, -DR1, -DR9, -DR15, -DR51
Results of HLA typing in transfused PRBCs
HLA Class I First PRBC:      A*32/A*31
                      B*15/B*51
Second PRBC: A*33/A*02
                      B*27/B*44
Not done
HLA Class II First PRBC:      DRB1*08/DRB1*04
Second PRBC: DRB1*15/DRB1*07
First PRBC: DRB1*04/DRB1*07
SaO2, the percentage of all the available heme binding sites saturated with oxygen; SpO2, saturation of hemoglobin with oxygen as measured by pulse oximetry; PRA, panel reactive 
antibody; HLA, human leukocyte antigen; PRBC, packed red blood cells; PC, platelet concentrates.
A B
Fig. 2. Chest radiography of the Case 2. (A) 4 day before the transfusion of platelet concentrates and packed red blood cells, showing mild pulmonary edema (B) shortly after 
TRALI develops, showing aggravated bilateral lung infiltrations.Lee JH, et al.  •  Transfusion-related Acute Lung Injury
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ries of PC and PRBC previously. 8 units of PC were transfused 
without any adverse transfusion reactions. However, after trans-
fusion of approximately 30mL of the first unit of PRBC, the pa-
tient complained of difficulty in breathing. SpO2 dropped to 
85%, so the transfusion was immediately discontinued. Since 
then, oxygen supplementation was required to maintain ade-
quate oxygenation. A chest radiography taken shortly after the 
onset of symptoms showed aggravated bilateral lung infiltra-
tions (Fig. 2B). Patient’s blood pressure was increased to 164/92 
mmHg from 114/60 mmHg, but it became normalized to 105/ 
61 mmHg after 2 and half hours. To differentiate TACO, blood 
pressure and clinical signs were carefully monitored. Further 
echocardiogram or BNP blood test were not done. However, 
TACO was less likely for worsening the patient’s pulmonary 
symptoms and signs when considering the facts that blood pres-
sure was decreased to the baseline level shortly after stopping 
transfusion and pulmonary edema with dyspnea was not im-
proved by diuretics therapy during hospitalization. Other clini-
cal entities which cause acute respiratory distress such as acute 
hemolytic transfusion reactions and anaphylactic transfusion 
reactions have been excluded in the same manner with the first 
case. 
  Similarly with the first case, patient’s serum after transfusion 
had multiple anti-HLA antibodies (36.5% PRA for HLA Class II) 
including anti-DR4 which was specific for HLA type of trans-
fused PRBC (Table 2).
  Based on the clinical and laboratory findings including the 
presence of patient’s anti-HLA antibodies which potentially 
could have reacted with donor’s leukocyte antigens, the diag-
nosis of TRALI that is responsible for worsening the patient’s re-
spiratory function which had pre-existing mild pulmonary ede-
ma has been made.
DISCUSSION
In 1983, Popovsky and Moore first identified “TRALI” as a dis-
tinct clinical entity (6). Recently TRALI has risen many concerns 
and awareness as the leading cause of transfusion-related mor-
tality. TRALI is defined as acute hypoxemia and non-cardiogen-
ic bilateral lung infiltrations, which presents as severe dyspnea, 
tachypnea and cyanosis, and develops during or within 6 hr af-
ter completion of transfusion (1). TRALI must be differentiated 
clinically from TACO and a variety of other conditions includ-
ing acute hemolytic transfusion reactions, anaphylactic transfu-
sion reactions, pulmonary embolism, acute myocardial infarc-
tion and bacterial contamination of the transfused product (7). 
  Like TRALI, TACO is increasingly being rediscovered as a com-
mon complication of transfusion. There are a lot of questions 
about the possibility of coexistence of TRALI and TACO and the 
difficulties in assigning transfusion-associated respiratory fail-
ure to a single cause, even when TACO can be demonstrated 
clearly (7, 8). TACO is defined by a combination of clinical signs 
such as post-transfusion hypertension, tachycardia, jugular vein 
distension, elevated central venous pressure and pulmonary 
artery occlusion pressure, pulmonary edema with cardiomega-
ly on chest radiography and the prompt response to diuretics or 
treatment of ischemia. BNP and N-terminal pro-BNP (NT-pro-
BNP), cardiac neurohormones specifically being secreted from 
the ventricles in response to volume expansion, pressure over-
load or hypoxemia, have been reported as useful markers for 
diagnosis or exclusion of TACO (8). However, Li and colleagues 
recently found that natriuretic peptides have limited diagnostic 
value in a differential diagnosis of pulmonary edema after trans-
fusion in the critically ill patients. Because BNP and NT-pro-BNP 
secretions were attributed to stimulatory effect of hypoxemia, as 
well as volume expansion and pressure overload and accuracy 
of BNP tests could be affected by the timing of the blood collec-
tion and other underlying diseases (5). Therefore, we can not 
totally depend on elevated BNP or NT-pro-BNP to differentiate 
TRALI from TACO in patients presenting dyspnea and hypox-
emia after transfusion. In our cases, the possibility of coexistence 
of TRALI and TACO couldn’t be excluded completely.
  All plasma containing blood components have been associ-
ated with development of TRALI, including whole blood, PRBC, 
PC, fresh frozen plasma (FFP), and rarely, cryoprecipitate, IV 
immunoglobulin, and stem cell preparations. Plasma rich blood 
components, such as FFP and PC were known to be most com-
monly implicated in TRALI (9). It was reported that almost any 
blood component containing about 50ml or more of plasma 
could be implicated in TRALI. Recently, one report showed that 
estimated residual plasma volume as low as 10-20 mL which 
contains donor derived leukocyte antibodies might cause TRA-
LI (10).
  The proposed pathogenesis of TRALI are multifactorial. The 
anti-HLA and anti-HNA antibodies and biologically active lipids 
in stored cellular blood components have been described (11). 
Most cases of TRALI has been so far considered to be caused by 
anti-HLA class I, anti-HLA class II, or anti-HNA antibodies in the 
donor’s plasma, which is called the major pathogenesis. Trans-
fusion of donor’s antibodies into a recipient who has the cognate 
antigens leads to neutrophil activation and release of oxidative 
substances that damage the pulmonary endothelium. This inju-
ry to pulmonary endothelium may cause an imbalance between 
the amount of fluid entering the alveoli and being actively re-
moved and then results in severe pulmonary edema (1, 3). 
  However, fewer than 10% of TRALI cases involve the reverse 
mechanism in which the recipient has anti-HLA or anti-HNA 
antibodies against donor’s leukocyte antigens (12). This minor 
pathogenesis supports the diagnosis of our two cases of TRALI. 
Due to relatively small number of leukocytes in the transfused 
blood components, it has been questioned whether TRALI can 
be caused by leukocyte antibodies in the patient’s serum. The Lee JH, et al.  •  Transfusion-related Acute Lung Injury
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development of TRALI even with a relatively few leukocytes 
transfused in our cases might be explained by the activation of 
the recipient’s own leukocytes either as a consequence of acti-
vating factors released by the small number of transfused leu-
kocytes after antibody binding or by an abnormal binding of 
the recipient’s alloantibodies to his/her own leukocytes. Leuko-
cyte antibodies in the recipient reacting with leukocytes in the 
blood product have also been described in several studies (1, 
13-15).
  TRALI has traditionally been associated with the infusion of 
anti-HLA class I antibodies in transfused blood components. 
However, TRALI caused by anti-HLA class II antibodies without 
simultaneous presence of anti-HLA class I antibodies have rare-
ly been described. In recent report, it has been suggested that 
anti-HLA class II antibodies play a critical role in initiating TRALI 
development (16). Proposed mechanism is that HLA class II-
expressing cells, such as monocytes, may lead to the production 
of IL-1β, TNF-α and tissue factors and release of these cytokines 
may result in the secondary activation of neutrophils and/or 
endothelial cells leading to endothelial damage, capillary leak, 
and eventually TRALI (12, 17, 18). Our second case supports the 
role of anti-HLA class II alone as the cause of TRALI.
  There has been international movement to reduce the risk of 
TRALI (11, 19). Most efforts are focusing on reducing of the use 
of plasma components from female donors. Since the donors 
of the implicated blood component in TRALI have been usually 
multiparous women who produced multiple antibodies against 
paternal leukocyte antigens during pregnancies. According to 
the 2008 Annual Serious Hazards of Transfusion (SHOT) report 
of UK, no case of TRALI due to FFP was reported in 2005, 2006 
and 2007, following the introduction of preferential use of FFP 
from male donors since late 2003. In 2008, observed rates of 
TRALI remain lower than those in 2003-2004 when TRALI risk 
reduction strategies were first initiated and no deaths occurred 
as a result of TRALI which is the lowest rate since 1996. Base on 
these, SHOT organization emphasizes the need to achieve 100% 
use of male FFP and plasma for platelet pooling across the UK (20). 
  In conclusion, TRALI must be considered as a serious but not 
infrequent adverse transfusion reaction which needs to be di-
agnosed promptly in a ways of clinical suspicion, and radiologi-
cal, biochemical and immunological findings and treated appro-
priately. Strategies and maximal efforts to prevent TRALI should 
be emphasized.
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